STAAR Surgical Company - 10-Q Summary
Business Context and Reporting Period
Company: STAAR Surgical Company (STAAR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 26, 2008
Business Overview: STAAR develops, manufactures, and sells visual implants and ophthalmic products, primarily intraocular lenses (IOLs) for cataract surgery and the Visian ICL for refractive surgery. Operations are global, with manufacturing in the U.S., Switzerland, and Japan. A significant event in this period was the full acquisition of the remaining 50% interest in its Japanese joint venture, Canon Staar, renamed STAAR Japan, Inc., effective December 29, 2007.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 26, 2008 |
9 Months Ended Sep 26, 2008 |
9 Months Ended Sep 28, 2007 |
|---|---|---|---|
| Net Sales | $18,112 | $56,737 | $43,478 |
| Gross Profit | $10,458 | $29,747 | $21,302 |
| Gross Margin | 57.7% | 52.4% | 49.0% |
| Operating Loss | $(1,426) | $(12,136) | $(10,489) |
| Net Loss | $(2,250) | $(13,735) | $(11,708) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.47) | $(0.42) |
| Cash and Equivalents (End of Period) | $6,697 | Balance Sheet Data | |
| Total Assets | $55,661 | Balance Sheet Data | |
| Total Liabilities | $24,111 | Balance Sheet Data | |
| Stockholders' Equity | $24,786 | Balance Sheet Data |
Note: Cash flow from operating activities for the nine months ended Sep 26, 2008, was a net use of $7.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33% for the quarter and 31% for the nine-month period compared to the prior year. This growth is primarily driven by the consolidation of STAAR Japan (contributing $9.1 million in the nine-month period) and favorable currency fluctuations ($2.4 million impact).
- Acquisition Impact: The acquisition of STAAR Japan resulted in a one-time $3.9 million loss on the settlement of a pre-existing distribution arrangement recorded in the first quarter of 2008. Additionally, purchase accounting rules required a $1.5 million write-up of acquired inventory, which reduced gross margins when sold.
- Geographic Shift: International sales now represent 75% of total revenue (up from 66% in the prior year), largely due to the inclusion of Japan.
- U.S. Performance: U.S. sales remained flat for the quarter and declined 4% for the nine-month period. While U.S. refractive sales (Visian ICL) grew 24%, cataract sales declined 10% due to market share erosion and competition.
- Liquidity: Cash and cash equivalents decreased from $10.9 million at year-end 2007 to $6.7 million at September 26, 2008, due to operating cash burn and acquisition-related costs.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Cash Flow: Management is focused on improving cash flow through cost-cutting (targeting $3.5 million in annualized U.S. savings) and increasing U.S. refractive sales.
- U.S. Refractive Growth: The Visian ICL is viewed as the key to profitability. Sales grew 24% in the U.S. for the nine months, driven by media exposure and a revised marketing strategy.
- Cataract Strategy: STAAR aims to reverse declining U.S. cataract sales by introducing aspheric IOLs and a Collamer Toric IOL to compete with Alcon.
- Japan Integration: Full integration of STAAR Japan is a strategic priority to control distribution and re-acquire worldwide rights to STAAR technology.
Risks and Contingencies:
- Litigation: STAAR is defending against two lawsuits (Moody and Parallax) filed by former regional representatives claiming damages totaling $80 million. No reserves have been established, but legal costs are substantial.
- Regulatory Delays: FDA approval for the Toric ICL (TICL) in the U.S. is on an "integrity hold" pending resolution of clinical oversight issues. Approval is critical for U.S. refractive growth.
- Economic Recession: As refractive surgery is elective, a global recession could reduce demand for Visian ICLs, though cataract sales (reimbursed) are less sensitive.
- Liquidity: The company has sufficient cash to meet requirements through Q3 2009 but may need additional financing if losses continue or if U.S. sales do not improve.
Investor Verification Checklist
- U.S. Cataract Sales Trend: Verify if the introduction of aspheric IOLs and the nanoPOINT injector is successfully halting the 10% year-to-year decline in U.S. cataract revenue.
- TICL FDA Status: Monitor the resolution of the FDA "integrity hold" on the Toric ICL application, as this is a critical path item for U.S. growth.
- Litigation Exposure: Track the progress of the Moody and Parallax lawsuits, specifically the timing of jury trials (expected Q4 2008 and early 2009) and potential legal cost overruns.
- Cash Burn Rate: Assess whether the $3.5 million cost-cutting target in the U.S. is being met to offset the cash burn from international expansion and integration costs.
- STAAR Japan Integration: Evaluate whether the integration of STAAR Japan is delivering the projected synergies and margin improvements without significant disruption to sales.